ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by goldennorthon Mar 31, 2021 10:46am

165 Views

Post# 32913665

Skill, Expertise and Professionalism.

ProMIS Neuroscieces has an outstanding, experenced and professional mamagment team. They have a vast number of scientific advisory board members who are world class and highly knowledgeable. The keys to medical achievement in several neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are on the horizon. Time will be the realization.

https://www.streetwisereports.com/article/2021/02/03/neurosciences-firm-provides-insight-on-recent-alzheimers-amyloid-field-developments.html

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security